Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis
Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional s...
Gespeichert in:
| Veröffentlicht in: | Chest 2007-03, Vol.131 (3), p.897-899 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 899 |
|---|---|
| container_issue | 3 |
| container_start_page | 897 |
| container_title | Chest |
| container_volume | 131 |
| creator | Collard, Harold R. Anstrom, Kevin J. Schwarz, Marvin I. Zisman, David A. |
| description | Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Fourteen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 m (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of “responders” (ie, ≥ 20% improvement in 6MWD) or “nonresponders” (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial. |
| doi_str_mv | 10.1378/chest.06-2101 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2098039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S001236921538911X</els_id><sourcerecordid>70257417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-e496030af782366ec369b9c1197d3cf4a52229876159c9818b11165086924b8c3</originalsourceid><addsrcrecordid>eNp1kc-P1CAYhonRuOPo0avpRW_d5SstPy4muro6ySaaqPFIKKXbb6VlhHaM_72Mnbh68EQID-_38kDIU6DnwIS8sINL8znlZQUU7pENKAYla2p2n2wohapkXFVn5FFKtzTvQfGH5AwEazgA3ZDXn9B3bjI9-mI37mM4uFR8Nf5b8QbTbCbrCpyKXYdhb-YBbfFx8WOYTPxZXGEbQ8L0mDzojU_uyWndki9Xbz9fvi-vP7zbXb66Lm1D2Vy6WnHKqOmFrBjnzuZirbK5keiY7WvTVFWlpODQKKskyBYAeENl7l-30rItebnm7pd2dJ110xyN1_uIY66jg0H978mEg74JB11RJSlTOeDFKSCG70vWpkdM1nlvJheWpAWtGlFnN1tSrqDND0zR9X-GANVH6_q3dU25PlrP_LO_m93RJ80ZeH4CTLLG9zGLxXTHSQ5ciSZzFys34M3wA6PTaTTe51i2jrwNS5yMBwaaaamOVcV6w2XzB3RRJ4suf1uXb9tZdwH_U_oXXVCuug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70257417</pqid></control><display><type>article</type><title>Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Collard, Harold R. ; Anstrom, Kevin J. ; Schwarz, Marvin I. ; Zisman, David A.</creator><creatorcontrib>Collard, Harold R. ; Anstrom, Kevin J. ; Schwarz, Marvin I. ; Zisman, David A.</creatorcontrib><description>Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Fourteen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 m (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of “responders” (ie, ≥ 20% improvement in 6MWD) or “nonresponders” (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.06-2101</identifier><identifier>PMID: 17356110</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: Elsevier Inc</publisher><subject>3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cardiology. Vascular system ; clinical trial ; Cyclic Nucleotide Phosphodiesterases, Type 5 ; Exercise Test - drug effects ; Female ; Follow-Up Studies ; Humans ; Hypertension, Pulmonary - drug therapy ; Male ; Medical sciences ; Middle Aged ; Phosphodiesterase Inhibitors - therapeutic use ; Piperazines - therapeutic use ; Pneumology ; pulmonary fibrosis ; Pulmonary Fibrosis - drug therapy ; pulmonary hypertension ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; Pulmonary Wedge Pressure - drug effects ; Purines - therapeutic use ; Respiratory system : syndromes and miscellaneous diseases ; sildenafil ; Sildenafil Citrate ; Sulfones - therapeutic use ; therapeutics ; Vascular Resistance - drug effects ; Vasodilator Agents - therapeutic use ; Walking</subject><ispartof>Chest, 2007-03, Vol.131 (3), p.897-899</ispartof><rights>2007 The American College of Chest Physicians</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-e496030af782366ec369b9c1197d3cf4a52229876159c9818b11165086924b8c3</citedby><cites>FETCH-LOGICAL-c503t-e496030af782366ec369b9c1197d3cf4a52229876159c9818b11165086924b8c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18616975$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17356110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Collard, Harold R.</creatorcontrib><creatorcontrib>Anstrom, Kevin J.</creatorcontrib><creatorcontrib>Schwarz, Marvin I.</creatorcontrib><creatorcontrib>Zisman, David A.</creatorcontrib><title>Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis</title><title>Chest</title><addtitle>Chest</addtitle><description>Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Fourteen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 m (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of “responders” (ie, ≥ 20% improvement in 6MWD) or “nonresponders” (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial.</description><subject>3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>clinical trial</subject><subject>Cyclic Nucleotide Phosphodiesterases, Type 5</subject><subject>Exercise Test - drug effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Piperazines - therapeutic use</subject><subject>Pneumology</subject><subject>pulmonary fibrosis</subject><subject>Pulmonary Fibrosis - drug therapy</subject><subject>pulmonary hypertension</subject><subject>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</subject><subject>Pulmonary Wedge Pressure - drug effects</subject><subject>Purines - therapeutic use</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><subject>sildenafil</subject><subject>Sildenafil Citrate</subject><subject>Sulfones - therapeutic use</subject><subject>therapeutics</subject><subject>Vascular Resistance - drug effects</subject><subject>Vasodilator Agents - therapeutic use</subject><subject>Walking</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc-P1CAYhonRuOPo0avpRW_d5SstPy4muro6ySaaqPFIKKXbb6VlhHaM_72Mnbh68EQID-_38kDIU6DnwIS8sINL8znlZQUU7pENKAYla2p2n2wohapkXFVn5FFKtzTvQfGH5AwEazgA3ZDXn9B3bjI9-mI37mM4uFR8Nf5b8QbTbCbrCpyKXYdhb-YBbfFx8WOYTPxZXGEbQ8L0mDzojU_uyWndki9Xbz9fvi-vP7zbXb66Lm1D2Vy6WnHKqOmFrBjnzuZirbK5keiY7WvTVFWlpODQKKskyBYAeENl7l-30rItebnm7pd2dJ110xyN1_uIY66jg0H978mEg74JB11RJSlTOeDFKSCG70vWpkdM1nlvJheWpAWtGlFnN1tSrqDND0zR9X-GANVH6_q3dU25PlrP_LO_m93RJ80ZeH4CTLLG9zGLxXTHSQ5ciSZzFys34M3wA6PTaTTe51i2jrwNS5yMBwaaaamOVcV6w2XzB3RRJ4suf1uXb9tZdwH_U_oXXVCuug</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>Collard, Harold R.</creator><creator>Anstrom, Kevin J.</creator><creator>Schwarz, Marvin I.</creator><creator>Zisman, David A.</creator><general>Elsevier Inc</general><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20070301</creationdate><title>Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis</title><author>Collard, Harold R. ; Anstrom, Kevin J. ; Schwarz, Marvin I. ; Zisman, David A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-e496030af782366ec369b9c1197d3cf4a52229876159c9818b11165086924b8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>clinical trial</topic><topic>Cyclic Nucleotide Phosphodiesterases, Type 5</topic><topic>Exercise Test - drug effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Piperazines - therapeutic use</topic><topic>Pneumology</topic><topic>pulmonary fibrosis</topic><topic>Pulmonary Fibrosis - drug therapy</topic><topic>pulmonary hypertension</topic><topic>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</topic><topic>Pulmonary Wedge Pressure - drug effects</topic><topic>Purines - therapeutic use</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><topic>sildenafil</topic><topic>Sildenafil Citrate</topic><topic>Sulfones - therapeutic use</topic><topic>therapeutics</topic><topic>Vascular Resistance - drug effects</topic><topic>Vasodilator Agents - therapeutic use</topic><topic>Walking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Collard, Harold R.</creatorcontrib><creatorcontrib>Anstrom, Kevin J.</creatorcontrib><creatorcontrib>Schwarz, Marvin I.</creatorcontrib><creatorcontrib>Zisman, David A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Collard, Harold R.</au><au>Anstrom, Kevin J.</au><au>Schwarz, Marvin I.</au><au>Zisman, David A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>131</volume><issue>3</issue><spage>897</spage><epage>899</epage><pages>897-899</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Fourteen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 m (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of “responders” (ie, ≥ 20% improvement in 6MWD) or “nonresponders” (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial.</abstract><cop>Northbrook, IL</cop><pub>Elsevier Inc</pub><pmid>17356110</pmid><doi>10.1378/chest.06-2101</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3692 |
| ispartof | Chest, 2007-03, Vol.131 (3), p.897-899 |
| issn | 0012-3692 1931-3543 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2098039 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors Aged Aged, 80 and over Biological and medical sciences Cardiology. Vascular system clinical trial Cyclic Nucleotide Phosphodiesterases, Type 5 Exercise Test - drug effects Female Follow-Up Studies Humans Hypertension, Pulmonary - drug therapy Male Medical sciences Middle Aged Phosphodiesterase Inhibitors - therapeutic use Piperazines - therapeutic use Pneumology pulmonary fibrosis Pulmonary Fibrosis - drug therapy pulmonary hypertension Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases Pulmonary Wedge Pressure - drug effects Purines - therapeutic use Respiratory system : syndromes and miscellaneous diseases sildenafil Sildenafil Citrate Sulfones - therapeutic use therapeutics Vascular Resistance - drug effects Vasodilator Agents - therapeutic use Walking |
| title | Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A52%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sildenafil%20Improves%20Walk%20Distance%20in%20Idiopathic%20Pulmonary%20Fibrosis&rft.jtitle=Chest&rft.au=Collard,%20Harold%20R.&rft.date=2007-03-01&rft.volume=131&rft.issue=3&rft.spage=897&rft.epage=899&rft.pages=897-899&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.06-2101&rft_dat=%3Cproquest_pubme%3E70257417%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70257417&rft_id=info:pmid/17356110&rft_els_id=S001236921538911X&rfr_iscdi=true |